Population pharmacokinetic analysis of the P2X3‐receptor antagonist gefapixant

• Egile Nagusiak: Akshita Chawla (Egilea), Anna Largajolli (Egilea), Azher Hussain (Egilea), Huub Kleijn (Egilea), Sihem Ait‐Oudhia (Egilea), Judith Anton (Egilea), Hari Krishna Ananthula (Egilea), Jesse Nussbaum (Egilea), Carmen La Rosa (Egilea), Ferdous Gheyas (Egilea)
• Formatua: Liburua
• Argitaratua: Wiley, 2023-08-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Gefapixant, a P2X3‐receptor antagonist, demonstrated objective and subjective efficacy in individuals with refractory or unexplained chronic cough. We report a population pharmacokinetic (PopPK) analysis that characterizes gefapixant pharmacokinetics (PKs), quantifies between‐ and within‐pa...